






Review

The COVID-19 Vaccines: Recent Development, Challenges and Prospects

Yuxin Yan ^{1,†}, Yoongxin Pang ^{2,†}, Zhuoyi Lyu ¹, Ruiqi Wang ², Xinyun Wu ², Chong You ³, Haitao Zhao ⁴, Sivakumar Manickam ⁵, Edward Lester ⁶, Tao Wu ^{1,7} and Chengheng Pang ^{2,8,*}

- ¹ Department of Chemical and Environmental Engineering, University of Nottingham Ningbo China, Ningbo 315100, China; yuxin.yan@nottingham.edu.cn (Y.Y.); slyzl6@nottingham.edu.cn (Z.L.); tao.wu@nottingham.edu.cn (T.W.)
 - ² New Materials Institute, University of Nottingham Ningbo China, Ningbo 315042, China; yoongxin.pang@nottingham.edu.cn (Y.P.); shyrrw2@nottingham.edu.cn (R.W.); xinyun.wu@nottingham.edu.cn (X.W.)
 - ³ Beijing International Center for Mathematical Research, Peking University, Beijing 100871, China; chongy@pku.edu.cn
 - ⁴ MITMECHE, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; haitaoz@mit.edu
 - ⁵ Petroleum and Chemical Engineering, Faculty of Engineering, Universiti Teknologi Brunei, Bandar Seri Begawan BE1410, Brunei; manickam.sivakumar@utb.edu.bn
 - ⁶ Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK; edward.lester@nottingham.ac.uk
 - ⁷ Key Laboratory for Carbonaceous Wastes Processing and Process Intensification Research of Zhejiang Province, University of Nottingham Ningbo China, Ningbo 315100, China
 - ⁸ Municipal Key Laboratory of Clean Energy Conversion Technologies, University of Nottingham Ningbo China, Ningbo 315100, China
- * Correspondence: chengheng.pang@nottingham.edu.cn
- † Both authors contributed equally to this work.



Citation: Yan, Y.; Pang, Y.; Lyu, Z.; Wang, R.; Wu, X.; You, C.; Zhao, H.; Manickam, S.; Lester, E.; Wu, T.; et al. The COVID-19 Vaccines: Recent Development, Challenges and Prospects. *Vaccines* **2021**, *9*, 349. <https://doi.org/10.3390/vaccines9040349>

Academic Editor: Ralph A. Tripp

Received: 4 March 2021

Accepted: 22 March 2021

Published: 5 April 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract: The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed drugs to control the outbreak. The development of COVID-19 vaccines is crucial for the world to return to pre-pandemic normalcy, and a collective global effort has been invested into protection against SARS-CoV-2. As of March 2021, thirteen vaccines have been approved for application whilst over 90 vaccine candidates are under clinical trials. This review focuses on the development of COVID-19 vaccines and highlights the efficacy and vaccination reactions of the authorised vaccines. The mechanisms, storage, and dosage specification of vaccine candidates at the advanced stage of development are also critically reviewed together with considerations for potential challenges. Whilst the development of a vaccine is, in general, in its infancy, current progress is promising. However, the world population will have to continue to adapt to the “new normal” and practice social distancing and hygienic measures, at least until effective vaccines are available to the general public.

Keywords: vaccines; COVID-19; global pandemic; coronavirus; SARS-CoV-2



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The ongoing pandemic of coronavirus disease (COVID-19) has impacted the world socially and economically on many different levels. COVID-19 is caused by a new strain of coronavirus known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), with a much higher transmission rate of around 2.2 per patient within China [1]. Phylogenetic analysis of the full sequence of SARS-CoV-2 suggests that the virus belongs to the subgenus Sarbecovirus in genus lineage B betacoronavirus genre [2] as the gene

sequence of SARS-CoV-2 is 89% identical to bat SARS-like coronavirus ZXC21 (bat-SL-CoVZXC21, accession no. MG772934.1) and ZC45 (MG772933.1); and it is 82% identical to SARS-CoV Tor2 (JX163927) [3]. Though its nucleotide has shown 96.2% similarity with the one of bat coronavirus at the whole genome level, the primary reservoir of SARS-CoV-2 has not been determined [4]. Researchers investigated the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human angiotensin-converting enzyme 2 (hACE2) and reported that SARS-CoV-2-CTD exhibited a stronger interaction at the binding interface as compared to SARS-receptor-binding domain (SARS-RBD) [5]. The binding profiles and affinity constants (K_D), i.e., SARS-CoV-2-S1 and SARS-CoV-2-CTD were recorded as 94.6 ± 6.5 nM and 133.3 ± 5.6 nM, respectively. Meanwhile, SARS-RBD engaging the same receptor was recorded as 408.7 ± 11.1 nM [5], which revealed that the atomic interactions between hACE2 and SARS-CoV-2-CTD are approximately four times higher than that with SARS-RBD. SARS-CoV-2 is both pathogenic and zoonotic, thereby allowing the transmission between animals and humans, leading to epidemic regionally and globally [3]. Research on the transmission dynamics of the SARS-CoV-2 revealed the transmissibility of SARS-CoV-2 is within the range of 0.8–5.7 [6–8]. More than a year since the detection of SARS-CoV-2, there have been over 121 million confirmed cases recorded and the disease has claimed over 2.7 million lives around the world as recorded on 20 March 2021. As the world population is adapting to what is being called the “new normal” of social distancing, mask-wearing, and temperature screening, an effective medical approach seems to be the only route for life to return to what it was pre-pandemic. Many countries have employed the former with the help of advanced science and technology where scientists and healthcare experts have come together to accelerate potential prophylactic and curative treatment to curb the spread and detrimental effect of the virus in the form of new, effective treatments and vaccines.

2. Disease Manifestations and Principles

2.1. Onset Condition

The SARS-CoV-2 is a betacoronavirus, and current research infers that the natural host may be bats [9]. This virus is known to strongly infect human respiratory and intestinal epithelial cells, as well as the neurological and central nervous system through the molecular mechanism of interaction between spike (S) protein and ACE2 receptors in the human body [10,11]. Jing et al. proposed an estimated incubation period model, which shows the median incubation time of COVID-19 to be 7.76 days [95% confidence interval (CI): 7.02 to 8.53], while 95 percentile to be 14.28 days (95% CI: 13.64 to 14.90) [12]. Infected patients may or may not be symptomatic but are infectious nonetheless. Most of the signs and symptoms of COVID-19 are similar to other respiratory or viral illnesses which include fever, chills, cough, shortness of breath, fatigue, muscle aches, headache, sore throat, loss of smell and taste, and congestion or runny nose. These symptoms may vary in individuals and as the disease progresses. Most COVID-19 patients develop mild (40%) or moderate (40%) symptoms, approximately 15% develop a severe disease that requires oxygen support, and 5% develop the critical disease with complications including respiratory failure, acute respiratory distress syndrome (ARDS), sepsis and septic shock, thromboembolism, and/or multi-organ failure [13,14]. Patients with other comorbidities (underlying non-communicable diseases) are at a higher risk for the disease to progress to a more critical stage.

Epidemiological studies have shown that the main transmission route of SARS-CoV-2 is through close contact and human-to-human transmission which occurs through droplets, aerosols, and contact [10]. Hence, many countries (but not all) have practiced, encouraged, and even enforced lockdown, social distancing, and mask-wearing.

2.2. Detection of Coronavirus in Plasma

Nucleic acid testing is required to identify if a patient is infected by SARS-CoV-2. The positive result from the new highly specific coronavirus nucleic acid test confirms

the diagnosis of COVID-19 [10,15]. Important pathogenic evidence for the diagnosis of COVID-19 infection, such as real-time fluorescent reverse transcriptase-polymerase chain reaction (RT-PCR) and gene sequencing technologies, have been included in the COVID-19 diagnosis and treatment specifications of the National Health Commission [16] to alleviate the impact of this pandemic on humans. Currently, nucleic acid detection based on the principle of RT-PCR is the main method for pathogen detection and disease diagnosis.

Antibody-based and genome-based detection methods are used to identify infections caused by SARS-CoV-2. The genome detection method provides a preliminary diagnosis, that is, identification by nasal swabs and throat swabs sampling. However, the sensitivity of such a detection method is relatively low. Antibody-based detection is a more sensitive approach performed by extracting and amplifying the viral RNA collected from the plasma of patients with abnormal body temperature, followed by qualitative and quantitative real-time determination if virus RNA is present in the patient [17]. In addition, the use of plasma viremia for diagnosis does not require nasopharyngeal aspiration, which avoids certain risks during specimen collection [18].

2.3. Treatment

Currently, there are no specific treatments for COVID-19 disease but clinical guidance for the management of suspected and confirmed COVID-19 patients are available for healthcare providers. However, these guidelines are not meant to replace clinical judgment or specialist consultation and are updated from time to time as new treatment options are available and approved based on research and clinical trial outcomes.

The pharmacological therapies generally administered in the management of COVID-19 patients are discussed.

2.3.1. Mild to Moderate COVID-19 Symptomatic Patients

WHO recommends that patients with suspected or confirmed mild to moderate COVID-19 symptoms be isolated to prevent virus transmission and they are given symptomatic treatment such as antipyretics for fever and pain, adequate nutrition, and appropriate rehydration [19]. The use of anti-bacterial therapy or prophylaxis is discouraged in these patients as it will contribute to higher bacterial resistance rates unless there is a clinical suspicion of a bacterial infection.

The National Institutes of Health (NIH) of United States of America mentions the use of SARS-CoV-2-neutralising-antibodies (bamlanivimab or casirivimab plus imdevimab) in outpatients who are at high risk for disease progression [20]. Anti-SARS-CoV-2 antibody-based therapies may have an effect before the host has mounted an effective immune response. This was based on preliminary data results of the observed reduction in COVID-19-related hospitalisation or emergency room visits within 28 days after treatment when compared to placebo. The investigational monoclonal antibody therapy was issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (USFDA) [21,22].

Patients being treated at home who developed symptoms with complications (e.g., difficulty in breathing, chest pain, etc.) should seek emergency help while patients in hospital should have close monitoring to recognise signs and symptoms of disease progression [23].

2.3.2. Severe COVID-19 Patients

WHO recommends immediate administration of supplemental oxygen therapy and emergency airway management to any patient with emergency signs (obstructed or absent breathing, severe respiratory distress, central cyanosis, shock, coma, and/or convulsions) and to any patient without emergency signs but with oxygen saturation (SpO_2) < 90%, to regulate the SpO_2 to a normal level of $\geq 94\%$ [23]. It is also recommended to ensure the SpO_2 of pregnant patients is $\geq 92\text{--}95\%$ whilst non-pregnant adults and child patients are $>90\%$.

The only anti-viral drug approved or authorised for temporary use in over 50 countries for the treatment of COVID-19 in severe hospitalised patients is remdesivir, the RNA-dependent RNA-polymerase (RdRp) inhibitor of the Ebola virus and is expected to have broad-spectrum antiviral effects [24]. It is an adenosine nucleotide analogue that can interrupt virus replication. Remdesivir was granted approval by the USFDA on 22 October 2020 and conditional marketing authorisation by the European Commission for the treatment in COVID-19 patients for adults and paediatric patients (12 years of age and older and weighing at least 40kg) based on the study of the National Institute of Allergy and Infectious Diseases Adaptive COVID-19 Treatment Trial (NIAID-ACTT-1). Study showed that remdesivir improved recovery time (10 days with 95% confidence interval (95% CI: 9 to 11) compared with 15 days (95% CI: 13 to 18) in the placebo arm (rate ratio for recovery, 1.29; 95% CI: 1.12 to 1.49; log-rank p -value < 0.0001) [25]. This suggests the administration of remdesivir could reduce hospitalisation time especially in severe disease patients requiring supplemental oxygen.

Another anti-viral drug widely used is favipiravir, a nucleoside analog and is metabolised in cells to a ribosyl triphosphate form (favipiravir RTP) that selectively inhibits RNA polymerase involved in influenza viral replication. It is used as an antiviral treatment for influenza A and B [26]. There were two open-label clinical studies conducted in China, one comparing favipiravir to lopinavir/ritonavir combination by Cai et al. [27] and another to arbidol group by Chen et al. [28]. From the studies, it was found that favipiravir had better viral clearance compared to the lopinavir/ritonavir combination; and compared to the arbidol group, it had a higher recovery rate after 7 days of antiretroviral treatment. A phase III clinical trial of favipiravir in COVID-19 patients with non-severe symptoms is ongoing in Japan and the latest results showed a reduction in recovery time (11.9 days in the favipiravir group compared to 14.7 days in the placebo group) [29].

2.3.3. Critical COVID-19 Patients

It is well known that the immunity of the human body decreases with age [30]. With the spread of the virus, elderly patients, especially those with comorbidities, are at a higher risk to suffer from COVID-19 symptoms [31]. Effective preventive measures are mandatory to reduce the risk of hospitalisation and death of the older population. One of such measures is the development of a safe and efficacious vaccine to protect the elderly from being infected by the virus [32]. Whilst good progress is being made in vaccine development, the standard operating procedure of COVID-19 management should be practised and retained as social responsibilities for the time being.

Most of the recommendations for the management of critically ill patients with COVID-19 are extrapolated from experiences with other causes of sepsis [33]. There is limited information to suggest that the critical care management of patients with COVID-19 should differ substantially from the management of other critically ill patients. However, taking special precautions to prevent environmental contamination by SARS-CoV-2 is warranted. As with any patient in the intensive care unit (ICU), successful clinical management of a patient with COVID-19 includes treating both the medical condition that initially resulted in ICU admission and other comorbidities and nosocomial complications.

3. Vaccine for SARS-CoV-2

3.1. Principles of Vaccine

The main structure of coronavirus includes a single-strand positive-strand nucleic acid (ssRNA), S protein, membrane protein (M), an envelope protein (E), and nucleocapsid protein (N). Amongst them, the S protein is responsible for recognising and binding to receptors on the surface of host cells and plays an important role in the first step of viral infection. Viral cell entry is facilitated by the fusion of viral and host cell membranes after the RBD of S protein binds to cellular ACE2. Studies have reported that the mechanical stability of SARS-CoV-2 RBD (250 pN) plays a vital role in increasing the spread of COVID-19 due to stronger intermolecular interactions as compared to RBD of SARS-CoV (200 pN) [34].

The energetic studies of RBD have provided additional information regarding the stabilisation of S protein during the transition from close to open conformation before ACE2 recognition [35]. This transition prepares the virus for binding, fusion, and release of viral RNA into the cytoplasm and outperforms SARS-CoV in withstanding Brownian and cellular forces to maintain close contact with ACE2 for a post-fusion mechanism to occur. In addition, the M and E proteins are responsible for virus assembly, and the N protein plays an important role in RNA synthesis [36].

As the genome sequences of SARS-CoV-2 and SARS-CoV are highly similar, and they have the same cellular receptor ACE2, knowledge from the development of the SARS-CoV vaccine is important and served as the basis to outline the development of SARS-CoV-2 vaccines [37]. Studies have shown that vaccines targeting the RBD, S1, or S2 subunit of SARS-CoV-2 exhibit certain protective effects against COVID-19 [38]. Thus, the new coronavirus vaccines that are currently under research are generally designed and developed to destabilise the S protein and disrupt or weaken the RBD interactions.

On 24 January 2020, the Chinese Center for Disease Control and Prevention successfully isolated China's first strain of new coronavirus [39]. Up to date, the global coronavirus vaccine research and development has covered various vaccine categories, including live virus and inactivated vaccines, subunit vaccines, vector vaccines, nucleic acid vaccines (mRNA vaccines and DNA vaccines), etc. [40].

3.1.1. Live Virus Vaccines and Inactivated Vaccines

Live virus and inactivated vaccines with high immunogenicity that provide excellent stimulation to the immune system for antibody generation have been widely applied in the biomedical industry. Live virus vaccine is synthesised by the virus with reduced virulence or even non-virulence; whilst inactivated vaccines contain non-infectious intact virus with low- or non-pathogenicity, and thus, would not proliferate *in vivo*. Whilst live virus vaccines are developed with reduced virulence, they are closely monitored to ensure the reduced virulence is not restored [41] for the safe administration both during clinical trials and commercialised applications. Codagenix and the Serum Institute of India are developing a live serum attenuated vaccine based on the CodaVax technology under the Phase I trial [42].

3.1.2. Subunit Vaccines

Subunit vaccines are composed primarily of non-genetic viral proteins or peptide fragments to trigger strong immune responses. The absence of an entire infectious virus in subunit vaccines increases the safety and eliminates the problem of virus inactivation or reversal of toxicity [41]. Studies have shown that most of the SARS-CoV-2 subunit vaccines target proteins, particularly the spike protein, or age proteins in specific areas; whilst some other subunit vaccines focus on N proteins. It aims to deliver antibodies and to contain human lymphocyte antigen (HLA) restricted T cell epitopes [43]. Israeli company MigVax is in the process of developing an oral anti-COVID-19 subunit vaccine based on previous research products [44]. At the same time, The Coalition for Epidemic Preparedness Innovations (CEPI) is working with the University of Queensland to develop a protein vaccine that uses “molecular clamps” to lock the coronavirus protein [45]. However, the study was terminated due to the potential risk of triggering Human Immunodeficiency Virus–false positives [46]. That being said, some other subunit vaccines have entered clinical trials, such as NVX CoV2373 in Phase III trial and SCB-2019 has completed Phase I trial [47].

3.1.3. Vector Vaccines

The vector-based vaccine is a live attenuated vaccine that uses a modified safe virus such as adenovirus, measles, and influenza as a vector to express coronavirus proteins during the immunisation process. Vector vaccines are categorised into replicating and non-replicating vectors based on their replicating potential. Many of these viral vectors could not, or can only perform limited replication in human cells, and thus, have minimum

safety concerns upon application. Viral vectors generally can perform quick synthesis of recombinants, verify protein expression, and accelerate the development of the immune system [41]. However, if the vaccine has been previously exposed to the targeted virus, the efficacy of the vaccine could be reduced due to the already existing immunity against the vector [48]. Currently, Hamilton, Massachusetts Institute of Technology (MIT), is cooperating with Oxford University to develop a chimpanzee adenovirus (serotype Y25) vectored SARS-CoV2 vaccine [49]. In addition to this, the Pasteur Institute, Themis, and the University of Pittsburgh Vaccine Research Center are developing a vaccine that expresses the SARS-CoV-2 S protein in a measles virus vector [50]. AZD1222, which expresses the native-like-spike protein of SARS-CoV-2, has been developed by the University of Oxford and AstraZeneca and is now in the combined Phase II/III trials [51].

3.1.4. Nucleic Acid Vaccines (mRNA Vaccines and DNA Vaccines)

Nucleic acid vaccines can be produced in bulk and at a low cost without utilising live viruses. As these are not virus-containing vaccines, there is relatively low or no risk associated with virulence or infection upon application [52]. However, at the current stage of research, the distribution of DNA vaccines is rather challenging as the required dosage is relatively large. On the other hand, RNA vaccines face challenges with *in vivo* transfection efficiency [41]. Up to March 2021, the INO-4800 vaccine is conducting Phase II trials, and the primary developer has also planned to test the vaccine against the newly emerged variants [53]. The Moderna vaccine has been approved for use in Switzerland whilst Phase III trials are being conducted. Pfizer and BioNTech have developed four mRNA-based formulations, including two nucleoside modified mRNAs, where one contains uridine whilst the other contains self-amplifying RNA [54]. In addition, Tongji University in China, Imperial College London, Karolinska Institute, and Cobra Biologics are in collaborations to develop DNA vaccines named Comirnaty, also known as BNT162b2 [55], that is now in the combined Phase II/III trial [56]. Imperial College London has also explored a 'self-amplifying' RNA vaccine but the project was terminated on 27 January 2021 due to rapid virus mutation [57].

3.2. Current Vaccine Research Progress

3.2.1. Time Frame

Under normal circumstances, the development of a new vaccine from pre-clinical trials until approval and licensing takes an average of 10 to 15 years. According to Amanat and Krammer (2020) [58], two significant steps are typically needed before a vaccine is tested in clinical trials. Vaccines are first tested for their ability to deliver protective immunity in suitable animal models, followed by the toxicity test of these vaccines on animals such as mice [59], ferrets [60], and monkeys [61] to ensure safety in application. Studies at the Chinese Academy of Sciences Wuhan Institute of Virology show that rhesus macaques infected with novel Coronavirus have symptoms similar to those of human COVID-19 patients [62]. Additionally, ferrets have lungs that are physiologically similar to those of humans, and thus, researchers can mimic certain aspects of COVID-19 in humans, including its spread, through ferret investigations [62]. Concerning the tests, Chinese researchers produced a purified inactivated SARS-CoV-2 vaccine candidate and tested it in mice, rats, and rhesus macaques to induce SARS-CoV-2-specific neutralising antibodies that proved successful [40]. After passing these two tests, the initial batches of this vaccine that are of current Good Manufacturing Practice (cGMP) quality are produced. Ideally, clinical trials will commence beginning with a Phase I trial to assess the safety of the candidate vaccine in humans, followed with a Phase II trial to determine the dosage to preliminarily prove the curative effect. The final Phase III trial is to demonstrate the efficacy and safety of the vaccine in a larger cohort. Eventually, the distribution of the vaccines adds 1 to 2 months to the whole timeline. The time frame for vaccine development to eventual marketing is illustrated in Figure 1.




Figure 1. Flow chart of vaccine development from biological feedstock to clinical trials and logistic chain for vaccine distribution.

Up to 20 March 2021, there are over 90 vaccine candidates in clinical development, with 22 of them undergoing Phase III clinical trials, 32 in Phase II trials, and 44 in Phase I trials [63–65]. WHO has set its success benchmark for COVID-19 vaccines with the highest at 70% efficacy under a protected duration of one year and the lowest threshold at 50% efficacy for 6 months [66]. The developed vaccines are bounded to be effective without raising safety concerns to the public that is receiving the vaccination. The vaccines will have to fulfil all regulatory requirements in terms of quality, efficacy, and safety before a marketing authorisation is granted. Table 1 summarises the ongoing Phase III trials of leading vaccines in March 2021, tabulated according to the timeline. Further details, including the official identifier number, trial period, trial population, study design, targeted outcome measure, and primary findings are tabulated in Table S1 under the supplementary document.

3.2.2. Safety and Efficacy of Vaccines

By March 2021, thirteen vaccines (tabulated in Table 2) have been authorised for use in many countries. These vaccines have been demonstrated to be effective in preventing the infection of COVID-19 at varying efficacy. In terms of prevention of symptoms, the efficacy of the vaccine Comirnaty (BNT162b2) is 95%, followed by Moderna COVID-19 Vaccine (mRNA-1273) of 94.5% and inactivated vaccine BBIBP-CorV of 86%, whilst BNT162b2 (87%) is less effective in the prevention of severe disease, compared to the other two vaccines (100%) [92–94].

Clinical trial results of COVID-19 Vaccine AstraZeneca (AZD1222) [95] report the specific antibodies peaked by day 28 after vaccination and remained elevated until day 56. The mild or moderate adverse events of AZD1222 vaccination can be potentially reduced by paracetamol (acetaminophen) prophylaxis. The vaccination of CoronaVac is found to diminish with increased age; thus, an increased dosage is recommended for the elderly population [96]. Researchers report that the participants receiving the Sputnik V vaccine during clinical trials did not show unexpected adverse events after the first and second injections [97]. The 100% efficacy of the EpiVacCorona vaccine is evaluated based on its immunological and preventative efficacy from phase I and II trial results [98]. Both Sputnik V and EpiVacCorona vaccines exhibit positive results but further details of the clinical trials are yet to be made available. Convidicea, a novel coronavirus vaccine that incorporates adenovirus type 5 vector, was recently developed by China's CanSino Biologics. Clinical trials showed that the specific T-cell response peaked at day 14 after vaccination whilst specific antibodies and neutralising antibodies increased significantly at day 14 and continued to peak for 28 days post-vaccination [99]. The trial reports 75–83% of vaccine recipients develop common mild or moderate adverse effects such as pain at the injection site and fever within 28 days post-vaccination, no serious adverse effects were recorded. Convidicea has been approved for use within the military in China and emergency use in Mexico. On 20 February 2021, Russia approved the use of a new vaccine named CoviVac; more than 3000 participants will be recruited for clinical trials and the studies are expected to be completed by November 2021 [100]. Following that, U.S. Food and Drug Administration issued emergency use authorisation for the Janssen COVID-10 Vaccine that allows distribution and use in individuals 18 years of age and older [101]. China National Medical Products Administration (NMPA) granted a conditional market authorisation to the new Wuhan-Sinopharm vaccine (the name is yet to be announced) in late February 2021 [102]. The vaccine was approved for emergency use for high-risk individuals in the country, particularly for healthcare workers. Phase I and II clinical trials reported that the Wuhan-Sinopharm vaccine demonstrated immunogenicity in two randomised placebo-controlled trials [103]. Results for the phase III trial of the Wuhan-Sinopharm vaccine, conducted in Peru, are yet to be made available. On the other hand, Uzbekistan authorised the ZF2001 vaccine for emergency use [104] on 1 March 2021. Research on this vaccine suggests that ZF2001 neutralises the South African variant of SARS-CoV-2 [105] and clinical trials are currently underway in China and Uzbekistan; and planned to begin in Malaysia, Ecuador, Indonesia, and Pakistan.

Apart from the efficacy, the accompanying adverse reactions also play an important role in evaluating the availability of these vaccines. Generally, there were no severe adverse reactions reported for people who have taken these vaccines and the mild side effects normally include headache, muscle/joint pain, fatigue, and so forth [103,106,107]. However, either efficacy or adverse effect needs to be evaluated solely for individuals with different ages, genders, and medical histories. For instance, Mahase suggested that people with a history of allergic reactions should avoid taking BNT162b2 vaccines, which may cause significant hypersensitivity.

Table 2. Authorised vaccines available for COVID-19 are arranged according to vaccine types in March 2021.

Vaccine Name	Vaccine Type	Primary Developers	Efficacy
Comirnaty, also known as BNT162b2	mRNA-based vaccine	Pfizer, BioNTech; Fosun Pharma	95% [108]
Moderna COVID-19 Vaccine, also known as mRNA-1273	mRNA-based vaccine	Moderna, U.S. Biomedical Advanced Research and Development Authority (BARDA), National Institute of Allergy and Infectious Diseases (NIAID)	94.5% [109]
CoronaVac	Inactivated vaccine	Sinovac	50–91% [110]
BBIBP-CorV	Inactivated vaccine	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	79% [111]
Covaxin	Inactivated vaccine	Bharat Biotech, Indian Council of Medical Research (ICMR)	81% [112]
CoviVac	Inactivated vaccine	Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products	Yet to be made available
Name yet to be announced	Inactivated vaccine	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	72.5% based on interim analysis [113]
AstraZeneca, also known as AZD1222 or Covishield in India	Vector vaccine (Adenovirus)	AstraZeneca, University of Oxford	70% [109]
Sputnik V, also known as Gam-Covid-Vac	Vector vaccine (Adenovirus Ad5 and Ad26)	Gamaleya Research Institute, Acellena Contract Drug Research and Development	92% [97]
Janssen COVID-19 Vaccine, also known as JNJ-78436735 or Ad26.COV2.S	Vector vaccine (Adenovirus Ad26)	Janssen Biotech Inc.—Janssen Pharmaceutical Company of Johnson & Johnson	76.7–85.4% for molecularly confirmed severe/critical COVID-19 patients [114].
Convidicea, also known as Ad5-nCoV	Vector vaccine (Adenovirus Ad5)	CanSino Biologics	65.7% in prevention and 90.98% in terminating severe symptoms (interim analysis) [115]
ZF2001	Vector vaccine (Recombinant vaccine)	Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences	Yet to be made available
EpiVacCorona	Subunit vaccine	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology	100% (Based on phase I and II trials) [98]

3.3. Challenges Encountered in Developing Vaccines and Current Progress

3.3.1. Efficacy and Safety

More than 100 vaccines are being developed in various countries [41], and the establishment of efficacious and safe vaccines is urgently needed to curb the current pandemic. As clinical trials and evaluation of vaccine efficacy by the vaccine dossiers are expedited, post-marketing surveillance will play an important role in discovering any new adverse reaction to the vaccine in post-authorisation safety studies (PASS) and real-world evidence reporting. Currently, the most common adverse side reactions to the BNT162b2 mRNA-based vaccine are pain at the injection site, fatigue and headaches though there have been several reports of subjects having an anaphylactic reaction after receiving the vaccine [56,116]. Hence, the Medicines and Healthcare products Regulatory Agency (MHRA) guidelines state that any person with a history of immediate onset anaphylaxis to a vaccine, medicine, or food should not receive the BNT162b2 mRNA-based vaccine [117].

3.3.2. Emergence of Coronavirus Variants

Variants of coronavirus have been detected in recent months due to virus mutation and adaptation to increase its survival [118]. B.1.1.7 (or VUI 202012/01) is one of the many variants that exhibit a much higher transmission rate than the original virus and that of the other variants at 71% (95% CI: 0.67 to 0.75) [119]. B.1.1.7, which is the dominant variant in the United Kingdom, is suspected to be associated with a higher risk of death as compared to other variants due to spontaneous and frequent conformational change in the spike protein with increased transmissibility [120]. Similarly, P.1 variant emerged with three mutations in the S protein RBD at K417T, E484K, and N501Y [121]. These mutations are found to affect the antigenic profile and transmissibility by disrupting the ability of antibody generation from previous natural infection or through vaccination. In South Africa, variant B.1.351 emerged independently of B.1.1.7 and has similar mutations in the spike protein. However, there is no current evidence to suggest that this variant has any impact on neutralising antibodies or affecting the disease severity [122].

A vaccine escape must not happen in the coming months in which the infection rate would increase due to ineffective vaccines against mutated viruses. If this were to occur, the vaccines will have to be updated or redesigned regularly and yearly vaccine immunisation against the coronavirus is expected.

3.3.3. Vaccine Distribution Challenges

The frontrunners in late-stage vaccine development, with reported interim analysis results of the vaccine being 95% effective in preventing COVID-19, is from the phase III clinical trials of the BNT162b2 mRNA-based vaccine candidate from Pfizer and BioNTech. The vaccine requires storage at $-70\text{ }^{\circ}\text{C}$ throughout the distribution process from the manufacturer's store to its intended destination [123]. Whilst stability studies at a temperature of $2\text{ to }8\text{ }^{\circ}\text{C}$ ($36\text{ to }46\text{ }^{\circ}\text{F}$) allow the vaccine to remain stable for 5 days, it requires critical and meticulous planning when the vaccine is being transferred from the specialised freezers to the healthcare professional fridge to prevent the vaccine from losing its effectiveness due to suboptimal storage condition. These storage conditions pose a challenge to vaccine distribution particularly to many parts of the world that are unable to store these vaccines at such low temperatures, as only specialised freezers can produce such ultra-cold storage conditions. This means that cities or areas that do not have the capability of an ultra-cold storage system will have to wait longer for other vaccine candidates that are stored at milder conditions.

The Moderna vaccine candidate reported their preliminary trial results of a 94% effectiveness of the vaccine in preventing COVID-19 [124]. The vaccine is expected to be stored at a less stringent storage condition, as compared to Pfizer and BioNTech mRNA-based vaccines, at $-20\text{ }^{\circ}\text{C}$ for 6 months and $2\text{ to }8\text{ }^{\circ}\text{C}$ for 30 days, which poses less of a challenge as most hospitals and pharmacies have facilities to store the vaccine. An ideal vaccine distribution pathway is already established in all the countries especially towards the challenging rural areas.

4. Conclusions

Whilst the development of vaccines for COVID-19 is a long and tedious, yet urgent process, promising progress has been made in recent months. Multiple vaccines have been prepared and extensive preclinical research has been conducted. It begins with animal model verification and those successful proceeding to clinical trials in humans. Under normal circumstances, these vaccines can be approved for marketing only after the phase III clinical trials have fully confirmed that the vaccines are safe and effective. However, due to the urgency of this pandemic, COVID-19 vaccines have been given conditional, emergency, or temporary use authorisation with high surveillance on their efficacy and safety profile post-authorisation. Whilst such progress is promising, it is necessary to strengthen the popularisation of prevention knowledge and containment measures to collectively control the spread of the pandemic with measures such as social distancing,

frequent hand washing, and mask-wearing in public areas. The world population will have to adapt to these new preventive measures in order to flatten the pandemic curve, at least until safe and effective vaccines are made available to the general public, particularly those most vulnerable.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/vaccines9040349/s1>.

Author Contributions: Conceptualization, C.P. and Y.Y.; methodology, Y.Y., Z.L., R.W., Y.P.; validation, C.P., Y.Y., C.Y., H.Z., S.M., E.L., T.W.; formal analysis, Y.Y., Y.P., Z.L., R.W., X.W., C.P.; investigation, Y.Y., Y.P., Z.L., R.W., X.W.; resources, C.P., T.W.; data curation, Y.Y., Y.P., Z.L., R.W., X.W.; writing—original draft preparation, Y.Y., Y.P., Z.L., R.W., X.W., C.Y., C.P.; writing—review and editing, Y.Y., C.Y., S.M., E.L., T.W., C.P.; visualization, Y.Y., Z.L., R.W., X.W.; supervision, C.P., T.W., E.L.; project administration, C.P.; funding acquisition, C.P., T.W.; All authors have read and agreed to the published version of the manuscript.

Funding: The authors also gratefully express gratitude to all parties who have contributed towards the success of this project, both financially and technically, especially the S&T Innovation 2025 Major Special Programme (grant number 2018B10022) and the Ningbo Natural Science Foundation Programme (grant number 2018A610069) funded by the Ningbo Science and Technology Bureau, China, as well as the UNNC FoSE Faculty Inspiration Grant, China. The Zhejiang Provincial Department of Science and Technology is also acknowledged for this research under its Provincial Key Laboratory Programme (2020E10018).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to acknowledge the heroic and noble work of all front-line medical and research staff who are contributing to the fight against the current global pandemic.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sun, P.; Lu, X.; Xu, C.; Sun, W.; Pan, B. Understanding of COVID-19 based on current evidence. *J. Med. Virol.* **2020**, *92*, 548–551. [[CrossRef](#)] [[PubMed](#)]
2. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *Lancet* **2020**, *395*, 565–574. [[CrossRef](#)]
3. Yan, Y.; Shin, W.I.; Pang, Y.X.; Meng, Y.; Lai, J.; You, C.; Zhao, H.; Lester, E.; Wu, T.; Pang, C.H. The first 75 days of novel coronavirus (SARS-CoV-2) outbreak: Recent advances, prevention, and treatment. *Int. J. Environ. Res. Public Health* **2020**, *17*, 2323. [[CrossRef](#)] [[PubMed](#)]
4. Phan, T. Novel coronavirus: From discovery to clinical diagnostics. *Infect. Genet. Evol.* **2020**, *79*, 104211. [[CrossRef](#)]
5. Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu, Y.; Yuen, K.-Y.; et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. *Cell* **2020**, *181*, 894–904.e9. [[CrossRef](#)]
6. Zhao, S.; Musa, S.S.; Lin, Q.; Ran, J.; Yang, G.; Wang, W.; Lou, Y.; Yang, L.; Gao, D.; He, D.; et al. Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. *J. Clin. Med.* **2020**, *9*, 388. [[CrossRef](#)] [[PubMed](#)]
7. Wu, J.T.; Leung, K.; Leung, G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. *Lancet* **2020**, *395*, 689–697. [[CrossRef](#)]
8. Zhao, Q.; Chen, Y.; Small, D.S. Analysis of the epidemic growth of the early 2019-nCoV outbreak using internationally confirmed cases. *medRxiv* **2020**. [[CrossRef](#)]
9. Bassetti, M.; Vena, A.; Giacobbe, D.R. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. *Eur. J. Clin. Investig.* **2020**, *50*, e13209. [[CrossRef](#)]
10. Li, T.-Z.; Xu, G.-G. Research updates of 2019 novel coronavirus disease (COVID-19) diagnosis and treatment. *Med. J. Chin. PLA* **2020**, 1–9, preprint.
11. Ghosh, S.; Malik, Y.S. Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses. *Microorganisms* **2020**, *8*, 1840. [[CrossRef](#)]
12. Qin, J.; You, C.; Lin, Q.; Hu, T.; Yu, S.; Zhou, X.-H. Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward follow-up study. *medRxiv* **2020**, *6*, eabc1202. [[CrossRef](#)]

13. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *Lancet* **2020**, *395*, 507–513. [[CrossRef](#)]
14. Surveillances, V. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. *China CDC Wkly.* **2020**, *2*, 113–122.
15. Benvenuto, D.; Giovanetti, M.; Ciccozzi, A.; Spoto, S.; Angeletti, S.; Ciccozzi, M. The 2019-new Coronavirus epidemic: Evidence for virus evolution. *J. Med. Virol.* **2020**, *92*, 455–459. [[CrossRef](#)]
16. Udugama, B.; Kadhiresan, P.; Kozłowski, H.N.; Malekjahani, A.; Osborne, M.; Li, V.Y.C.; Chen, H.; Mubareka, S.; Gubbay, J.B.; Chan, W.C.W. Diagnosing COVID-19: The Disease and Tools for Detection. *ACS Nano* **2020**, *14*, 3822–3835. [[CrossRef](#)] [[PubMed](#)]
17. Grant, P.R.; Garson, J.A.; Tedder, R.S.; Chan, P.K.; Tam, J.S.; Sung, J.J. Detection of SARS Coronavirus in Plasma by Real-Time RT-PCR. *N. Engl. J. Med.* **2003**, *349*, 2468–2469. [[CrossRef](#)]
18. Tsang, K.; Mok, T.; Wong, P.; Ooi, G. Severe acute respiratory syndrome (SARS) in Hong Kong. *Respirology* **2010**, *8*, 259–265. [[CrossRef](#)] [[PubMed](#)]
19. World Health Organization. *Home Care for Patients with COVID-19 Presenting with Mild Symptoms and Management of Their Contacts: Interim Guidance, 17 March 2020*; WHO: Geneva, Switzerland, 2020.
20. National Institutes of Health. *COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines*; National Institutes of Health: New York, NY, USA, 2020.
21. Mahase, E. Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients. *BMJ* **2020**, *371*, m4362. [[CrossRef](#)]
22. Jain, U. The Evolving Armamentarium of COVID-19 Therapeutics. *ASA Monit.* **2021**, *85*, 32–33. [[CrossRef](#)]
23. World Health Organization. *Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected: Interim Guidance, 13 March 2020*; WHO: Geneva, Switzerland, 2020.
24. Gordon, C.J.; Tchesnokov, E.P.; Feng, J.Y.; Porter, D.P.; Gtze, M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. *J. Biol. Chem.* **2020**, *295*, 4773–4779. [[CrossRef](#)]
25. Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S. Remdesivir for the treatment of Covid-19—Preliminary report. *N. Engl. J. Med.* **2020**. [[CrossRef](#)] [[PubMed](#)]
26. Pharmaceuticals and Medical Devices Agency. *Report on the Deliberation Results. Dapagliflozin*; Pharmaceuticals and Medical Devices Agency: Tokyo, Japan, 2014.
27. Cai, Q.; Yang, M.; Liu, D.; Chen, J.; Shu, D.; Xia, J.; Liao, X.; Gu, Y.; Cai, Q.; Yang, Y. Experimental treatment with favipiravir for COVID-19: An open-label control study. *Engineering* **2020**, *6*, 1192–1198. [[CrossRef](#)] [[PubMed](#)]
28. Chen, C.; Huang, J.; Cheng, Z.; Wu, J.; Chen, S.; Zhang, Y.; Chen, B.; Lu, M.; Luo, Y.; Zhang, J. Favipiravir versus arbidol for COVID-19: A randomized clinical trial. *medRxiv* **2020**. [[CrossRef](#)]
29. Jean, S.-S.; Lee, P.-I.; Hsueh, P.-R. Treatment options for COVID-19: The reality and challenges. *J. Microbiol. Immunol. Infect.* **2020**, *53*, 436–443. [[CrossRef](#)]
30. Vasto, S.; Malavolta, M.; Pawelec, G. Age and immunity. *Immun. Ageing* **2006**, *3*, 2. [[CrossRef](#)] [[PubMed](#)]
31. Pawelec, G.; Weng, N.P. Can an effective SARS-CoV-2 vaccine be developed for the older population? *Immun. Ageing* **2020**, *17*, 8. [[CrossRef](#)] [[PubMed](#)]
32. Lee, J.-K. We Need More Public Hospitals and to Review Rapidly Possibility of Therapeutics as a COVID-19 Mitigation Strategy to Prevent the Collapse of the National Health Care Service. *Osong Public Health Res. Perspect.* **2020**, *11*, 343–344. [[CrossRef](#)]
33. Alhazzani, W.; Møller, M.H.; Arabi, Y.M.; Loeb, M.; Gong, M.N.; Fan, E.; Oczkowski, S.; Levy, M.M.; Derde, L.; Dzierba, A. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Med.* **2020**, *46*, 1–34. [[CrossRef](#)]
34. Moreira, R.A.; Chwastyk, M.; Baker, J.L.; Guzman, H.V.; Poma, A.B. Quantitative determination of mechanical stability in the novel coronavirus spike protein. *Nanoscale* **2020**, *12*, 16409–16413. [[CrossRef](#)] [[PubMed](#)]
35. Moreira, R.A.; Guzman, H.V.; Boopathi, S.; Baker, J.L.; Poma, A.B. Characterization of Structural and Energetic Differences between Conformations of the SARS-CoV-2 Spike Protein. *Materials* **2020**, *13*, 5362. [[CrossRef](#)] [[PubMed](#)]
36. Kuba, K.; Imai, Y.; Rao, S.; Gao, H.; Guo, F.; Guan, B.; Huan, Y.; Yang, P.; Zhang, Y.; Deng, W. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat. Med.* **2005**, *11*, 875. [[CrossRef](#)]
37. Ma, C.; Su, S.; Wang, J.; Wei, L.; Du, L.; Jiang, S. From SARS-CoV to SARS-CoV-2: Safety and broad-spectrum are important for coronavirus vaccine development. *Microbes Infect.* **2020**, *22*, 245–253. [[CrossRef](#)] [[PubMed](#)]
38. Zhang, H.; Penninger, J.M.; Li, Y.; Zhong, N.; Slutsky, A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. *Intensive Care Med.* **2020**, *46*, 586–590. [[CrossRef](#)]
39. World Health Organization. *Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), 24 February 2020*; WHO: Geneva, Switzerland, 2020.
40. Gao, Q.; Bao, L.; Mao, H.; Wang, L.; Xu, K.; Yang, M.; Li, Y.; Zhu, L.; Wang, N.; Lv, Z.; et al. Development of an inactivated vaccine for SARS-CoV-2. *Science* **2020**. [[CrossRef](#)]
41. Poland, G.A.; Ovsyannikova, I.G.; Crooke, S.N.; Kennedy, R.I.B. SARS-CoV-2 Vaccine Development: Current Status. *Mayo Clin. Proc.* **2020**, *95*, 2172–2188. [[CrossRef](#)]

42. Mueller, S.; Stauff, C.B.; Kalker, R.; Koidei, F.; Kushnir, A.; Tasker, S.; Coleman, J.R. A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates. *Vaccine* **2020**, *38*, 2943–2948. [[CrossRef](#)] [[PubMed](#)]
43. Zheng, N.; Xia, R.; Yang, C.; Yin, B.; Li, Y.; Duan, C.; Liang, L.; Guo, H.; Xie, Q. Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice. *Vaccine* **2009**, *27*, 5001–5007. [[CrossRef](#)]
44. Meir, R.; Krispel, S.; Simanov, L.; Eliahu, D.; Maharat, O.; Pitcovski, J. Immune responses to mucosal vaccination by the recombinant A1 and N proteins of infectious bronchitis virus. *Viral Immunol.* **2012**, *25*, 55–62. [[CrossRef](#)]
45. Watterson, D.; Wijesundara, D.; Modhiran, N.; Mordant, F.; Li, Z.; Avumegah, M.S.; McMillan, C.; Lackenby, J.; Guilfoyle, K.; Xplore, V.; et al. Molecular clamp stabilised Spike protein for protection against SARS-CoV-2. *Res. Sq.* **2020**. preprint. [[CrossRef](#)]
46. McIntyre, P.; Joo, Y.J.; Chiu, C.; Flanagan, K.; Macartney, K. COVID-19 vaccines—are we there yet? *Aust. Prescr.* **2021**, *44*, 19. [[CrossRef](#)]
47. Won, J.-H.; Lee, H. The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. *Int. J. Mol. Sci.* **2020**, *21*, 9775. [[CrossRef](#)] [[PubMed](#)]
48. Ura, T.; Okuda, K.; Shimada, M. Developments in viral vector-based vaccines. *Vaccines* **2014**, *2*, 624–641. [[CrossRef](#)] [[PubMed](#)]
49. Vandenberghe, L.H. COVID-19: Gene Transfer to the Rescue? *Hum. Gene Ther.* **2020**, *31*, 605–607. [[CrossRef](#)]
50. University of Pittsburgh Medical Center. Researchers in Pittsburgh, Paris and Vienna Win Grant for COVID-19 Vaccine. 2020. Available online: <https://www.upmc.com/media/news/032020-cepi-grant> (accessed on 25 December 2020).
51. Sah, R.; Shrestha, S.; Mehta, R.; Sah, S.K.; Raaban, A.R.; Dharma, K.; Rodriguez-Morales, A.J. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges and solutions in Nepal. *Travel Med. Infect. Dis.* **2021**, *40*, 101989. [[CrossRef](#)] [[PubMed](#)]
52. Yang, Z.-Y.; Kong, W.-P.; Huang, Y.; Roberts, A.; Murphy, B.R.; Subbarao, K.; Nabel, G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature* **2004**, *428*, 561–564. [[CrossRef](#)]
53. Gooch, K.; Smith, T.; Salguero, F.; Fotheringham, S.; Watson, R.; Dennis, M.; Handley, A.; Humphries, H.; Longet, S.; Tipton, T. One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model. *Nat. Portf.* **2021**. preprint. [[CrossRef](#)]
54. Mulligan, M.J.; Lyke, K.E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Raabe, V.; Bailey, R.; Swanson, K.A.; et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* **2020**, *586*, 589–593. [[CrossRef](#)]
55. Xinhua. Global Efforts to Combat Novel Coronavirus Focus on Vaccine Development. *Xin Hua News*, 8 February 2020.
56. Walsh, E.E.; Frenck, R.; Falsey, A.R.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Mulligan, M.J.; Bailey, R. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. *medRxiv* **2020**. [[CrossRef](#)]
57. McKay, P.F.; Hu, K.; Blakney, A.K.; Samnuan, K.; Bouton, C.R.; Rogers, P.; Polra, K.; Lin, P.J.; Barbosa, C.; Tam, Y. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients. *bioRxiv* **2020**. [[CrossRef](#)]
58. Amanat, F.; Krammer, F. SARS-CoV-2 Vaccines: Status Report. *Immunity* **2020**, *52*, 583–589. [[CrossRef](#)]
59. Sharma, O.; Sultan, A.A.; Ding, H.; Trigg, C.R. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Front. Immunol.* **2020**, *11*, 2413. [[CrossRef](#)] [[PubMed](#)]
60. Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. *Science* **2020**, *368*, 1016–1020. [[CrossRef](#)] [[PubMed](#)]
61. Muñoz-Fontela, C.; Dowling, W.E.; Funnell, S.G.P.; Gsell, P.-S.; Riveros-Balta, A.X.; Albrecht, R.A.; Andersen, H.; Baric, R.S.; Carroll, M.W.; Cavaleri, M.; et al. Animal models for COVID-19. *Nature* **2020**, *586*, 509–515. [[CrossRef](#)]
62. Ewen, C. Labs rush to study coronavirus in transgenic animals—Some are in short supply. *Nature* **2020**, *579*, 183.
63. World Health Organization. *Draft Landscape and Tracker of COVID-19 Candidate Vaccines*; World Health Organization: Geneva, Switzerland, 2021.
64. Parker, E.P.; Shrotri, M.; Kampmann, B. Keeping track of the SARS-CoV-2 vaccine pipeline. *Nat. Rev. Immunol.* **2020**, *20*, 650. [[CrossRef](#)] [[PubMed](#)]
65. Carl Zimmer, J.C.; Wee, S.-L. Coronavirus Vaccine Tracker. 2021. Available online: <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html> (accessed on 25 December 2020).
66. Sagonowsky, E. FDA Will Require 50% Efficacy for COVID-19 Vaccines. How High Is That Bar? 2020. Available online: <https://www.fiercepharma.com/vaccines/fda-to-require-at-least-50-efficacy-for-covid-19-vaccines-wsj> (accessed on 28 December 2020).
67. U.S. National Library of Medicine. *Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates against COVID-19 in Healthy Individuals*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
68. U.S. National Library of Medicine. *A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 against COVID-19 in Healthy Participants*; U.S. National Library of Medicine: Bethesda, MD, USA, 2021.
69. U.S. National Library of Medicine. *Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older*; U.S. National Library of Medicine: Bethesda, MD, USA, 2021.
70. U.S. National Library of Medicine. *A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.

71. U.S. National Library of Medicine. *A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (TeenCove)*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
72. U.S. National Library of Medicine. *Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
73. U.S. National Library of Medicine. *Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine (COVID-19)*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
74. U.S. National Library of Medicine. *Clinical Trial for SARS-CoV-2 Vaccine (COVID-19)*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
75. Chinese Clinical Trial Registry. *A Phase III Clinical Trial for Inactivated Novel Coronavirus Pneumonia (COVID-19) Vaccine (Vero Cells)*; Chinese Clinical Trial Registry: Beijing, China, 2020.
76. India National Institute of Medical Statistics. *A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Immunogenicity, and Lot-to-Lot Consistency of BBV152, a Whole Virion Inactivated Vaccine in Adults Greater than or Equal to 18 Years of Age*; NIMS: New Delhi, India, 2020.
77. U.S. National Library of Medicine. *Investigating a Vaccine against COVID-19*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
78. U.S. National Library of Medicine. *Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine against COVID-19 (RESIST)*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
79. U.S. National Library of Medicine. *A Study of Ad26.COV2.S in Adults (COVID-19)*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
80. U.S. National Library of Medicine. *A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adults (ENSEMBLE 2)*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
81. U.S. National Library of Medicine. *Phase III Trial of a COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
82. U.S. National Library of Medicine. *A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
83. U.S. National Library of Medicine. *Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
84. U.S. National Library of Medicine. *Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
85. U.S. National Library of Medicine. *A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
86. U.S. National Library of Medicine. *Phase II/III Study of COVID-19 DNA Vaccine (AG0302-COVID19)*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
87. U.S. National Library of Medicine. *A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-Protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)*; U.S. National Library of Medicine: Bethesda, MD, USA, 2021.
88. U.S. National Library of Medicine. *The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing against COVID-19*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
89. India National Institute of Medical Statistics. *A Prospective, Randomized, Adaptive, Phase I/II Clinical Study to Evaluate the Safety and Immunogenicity of Novel Corona Virus—2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by Intradermal Route in Healthy Subjects*; NIMS: New Delhi, India, 2020.
90. U.S. National Library of Medicine. *Study of GRAd-COV2 for the Prevention of COVID-19 in Adults (COVITAR)*; U.S. National Library of Medicine: Bethesda, MD, USA, 2021.
91. U.S. National Library of Medicine. *Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine*; U.S. National Library of Medicine: Bethesda, MD, USA, 2020.
92. De Soto, J.A. Evaluation of the Moderna, Pfizer/biontech, Astrazeneca/oxford and Sputnik V Vaccines for COVID-19. *J. Med. Clin. Sci.* **2020**. preprint. [\[CrossRef\]](#)
93. Logunov, D.Y.; Dolzhikova, I.V.; Zubkova, O.V.; Tukhvatullin, A.I.; Shcheblyakov, D.V.; Dzharullaeva, A.S.; Grousova, D.M.; Erokhova, A.S.; Kovyrshina, A.V.; Botikov, A.G. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. *Lancet* **2020**, *396*, 887–897. [\[CrossRef\]](#)
94. Chen, Y.W.; Yiu, C.-P.; Wong, K.-Y. Prediction of the 2019-nCoV 3C-like protease (3CLpro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. *ChemRxiv* **2020**. [\[CrossRef\]](#)
95. Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E.A.; et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* **2020**, *396*, 467–478. [\[CrossRef\]](#)
96. Zhang, Y.; Zeng, G.; Pan, H.; Li, C.; Kan, B.; Hu, Y.; Mao, H.; Xin, Q.; Chu, K.; Han, W.; et al. Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18–59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial. *medRxiv* **2020**. [\[CrossRef\]](#)
97. Roxby, P. Russian Covid Vaccine Shows Encouraging Results. *BBC News*, 11 November 2020.

98. BELTA News. Russia Reports 100% Efficacy of EpiVacCorona Vaccine, in Belarusian Telegraph Agency. *BELTA News*, 19 January 2021.
99. Zhu, F.-C.; Li, Y.-H.; Guan, X.-H.; Hou, L.-H.; Wang, W.-J.; Li, J.-X.; Wu, S.-P.; Wang, B.-S.; Wang, Z.; Wang, L.; et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet* **2020**, *395*, 1845–1854. [[CrossRef](#)]
100. Ministry of Science and Higher Education of the Russian Federation. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences. 2021. Available online: <http://www.chumakovs.ru/en/> (accessed on 4 January 2021).
101. U.S. Food and Drug Administration. Janssen COVID-19 Vaccine—Fact Sheets and Additional Information. 2021. Available online: <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine> (accessed on 25 December 2020).
102. National Medical Products Administration. *NMPA Conditionally Approves COVID-19 Vaccine Developed by Sinopharm's Wuhan Institute*; NMPA: Beijing, China, 2021.
103. Xia, S.; Duan, K.; Zhang, Y.; Zhao, D.; Zhang, H.; Xie, Z.; Li, X.; Peng, C.; Zhang, Y.; Zhang, W.; et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. *JAMA* **2020**, *324*, 951–960. [[CrossRef](#)] [[PubMed](#)]
104. An, Y.; Li, S.; Jin, X.; Han, J.-b.; Xu, K.; Xu, S.; Han, Y.; Liu, C.; Zheng, T.; Liu, M.; et al. A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates. *bioRxiv* **2021**. [[CrossRef](#)]
105. Huang, B.; Dai, L.; Wang, H.; Hu, Z.; Yang, X.; Tan, W.; Gao, G.F. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. *bioRxiv* **2021**. [[CrossRef](#)]
106. Poland, G.A.; Ovsyannikova, I.G.; Kennedy, R.B. SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates. *Lancet* **2020**, *396*, 1595–1606. [[CrossRef](#)]
107. Anderson, E.J.; Roupheal, N.G.; Widge, A.T.; Jackson, L.A.; Roberts, P.C.; Makhene, M.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; Pruijssers, A.J. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. *N. Engl. J. Med.* **2020**, *383*, 2427–2438. [[CrossRef](#)]
108. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N. Engl. J. Med.* **2020**, *383*, 2603–2615. [[CrossRef](#)]
109. Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Borat, Q.E.; et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* **2021**, *397*, 99–111. [[CrossRef](#)]
110. BBC News. Sinovac: Brazil Results show Chinese Vaccine 50.4% Effective. *BBC News*, 13 January 2021.
111. BBC News. Covid-19: China Approves Sinopharm Vaccine for General Use. *BBC News*, 31 December 2020.
112. Bharat Biotech. COVAXIN[®]—India's First Indigenous COVID-19 Vaccine. 2021. Available online: <https://www.bharatbiotech.com/covaxin.html> (accessed on 1 March 2021).
113. Liu, R.; Woo, R. Sinopharm's Wuhan Unit Reports 72.5% Efficacy for COVID Shot, Seeks Approval in China. *Reuters*, 24 February 2021.
114. U.S. Food and Drug Administration. *COVID-19 Vaccine Ad26.COV2.S, VAC31518 (JNJ-78436735)—Sponsor Briefing Document*; FDA: White Oak, MD, USA, 2021.
115. Gibran Naiyyar Peshimam. CanSinoBIO's COVID-19 Vaccine 65.7% Effective in Global Trials, Pakistan Official Says. *Reuters*, 8 February 2021.
116. Garvey, L.H.; Nasser, S. Allergic reactions to the first COVID-19 vaccine: Is polyethylene glycol (PEG) the culprit? *Br. J. Anaesth.* **2020**. [[CrossRef](#)]
117. Arthur, R. Pfizer COVID-19 Vaccine not to be Given to People with History of Anaphylaxis MHRA. *Biopharma Reporter*, 10 December 2020.
118. Singh, J.; Samal, J.; Kumar, V.; Sharma, J.; Agrawal, U.; Ehtesham, N.Z.; Sundar, D.; Rahman, S.A.; Hira, S.; Hasnain, S.E. Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications. *Viruses* **2021**, *13*, 439. [[CrossRef](#)]
119. Mahase, E. Covid-19: What have we learnt about the new variant in the UK? *BMJ* **2020**, *371*, m4944. [[CrossRef](#)]
120. Mallapaty, S. What's the risk of dying from a fast-spreading COVID-19 variant? *Nature* **2021**, *590*, 191–192. [[CrossRef](#)] [[PubMed](#)]
121. Hirotsu, Y.; Omata, M. Discovery of SARS-CoV-2 strain of P.1 lineage harboring K417T/E484K/N501Y by whole genome sequencing in the city, Japan. *medRxiv* **2021**. [[CrossRef](#)]
122. Centers for Disease Control and Prevention. *Emerging SARS-CoV-2 Variants*; CDC: Atlanta, GA, USA, 2021.
123. Mahase, E. Covid-19: Pfizer and BioNTech submit vaccine for US authorisation. *BMJ* **2020**, *371*, m4552. [[CrossRef](#)] [[PubMed](#)]
124. D'Agostini, G.; Esposito, A. Inferring Vaccine Efficacies and Their Uncertainties. A Simple Model Implemented in JAGS/rjags. Available online: <https://www.roma1.infn.it/~{dagos/covid19w.pdf> (accessed on 25 February 2021).